Mechanisms of action of absorbable hypolipidemic drugs.
D000818:Animals; D053304:Apolipoprotein C-II; D001056:Apolipoproteins C / Q000097:blood; D008076:Cholesterol, HDL / Q000378:metabolism; D004789:Enzyme Activation / Q000187:drug effects; D006801:Humans; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000494:pharmacology*; D008071:Lipoprotein Lipase / Q000378:metabolism; D008074:Lipoproteins / Q000378:metabolism; D008079:Lipoproteins, VLDL / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008830:Microbodies / Q000378:metabolism; D051381:Rats; D011973:Receptors, LDL / Q000187:drug effects / Q000378:metabolism; D013329:Structure-Activity Relationship
D053304:Apolipoprotein C-II; D001056:Apolipoproteins C; D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents; D008074:Lipoproteins; D008079:Lipoproteins, VLDL; D011973:Receptors, LDL; C036053:VLDL receptor; D008071:Lipoprotein Lipase